Caris Life Sciences, Inc. CAI 深 滬
已收盤 12-19 16:00:00 美东时间
27.94
+0.080
+0.29%
華盛通- 最 高28.44
- 今 開27.86
- 成交量 416.49万股
- 最 低 27.75
- 昨 收 27.86
- 總市值 78.51亿
- 52周最高 42.50
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 22.86
- 委 比 94.49%
- 總股本 2.81亿
- 歷史最高 42.50
- 量 比 1.91
- 振 幅 2.48%
- 歷史最低 22.86
- 每 手 1
- 風險率 3.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Caris Life Sciences' Caris Discovery Signs License Agreement With Genentech To Identify, Validate Oncology Targets In Solid Tumor Tissue
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that its therapeutic research arm, Caris Discovery, has
12-16 21:37
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Canaccord Genuity Initiates Coverage On Caris Life Sciences with Hold Rating, Announces Price Target of $28
Canaccord Genuity analyst Kyle Mikson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Hold rating and announces Price Target of $28.
12-02 20:31
High-Yield Alert: Calamos' New Nasdaq ETF Targets Nearly 18% Payouts
CAIQ, a new Nasdaq-linked ETF debuting with a nearly 18% coupon, aims to capture rising demand for high-yield, nontraditional income strategies.
11-25 05:04
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class
IRVING, Texas, Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announce...
11-21 21:30
Caris Life Sciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
Caris Life Sciences shares are trading higher after the company reported better...
11-06 06:13
Caris Life Sciences Raises FY2025 Sales Guidance from $675.000M-$685.000M to $720.000M-$730.000M vs $680.242M Est
2025 Financial Outlook and GuidanceCaris Life Sciences expects full year 2025 revenue to be in the range of $720.0 million to $730.0 million, representing growth of 75% to 77% compared to full year 2024. Clinical therapy
11-06 05:37
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Meta股价因税务支出拖累盈利下跌，公司称明年人工智能投资将“显著增加”
专题：聚焦2025年第三季度美股财报 Meta（股票代码：META）于周三发布第三季度财报，其营收超出市场预期，但受一次...
10-30 17:12
